{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:41:41Z","timestamp":1791196901715,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00198-015-3109-y","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T08:23:30Z","timestamp":1428913410000},"page":"1667-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["The position of strontium ranelate in today\u2019s management of osteoporosis"],"prefix":"10.1007","volume":"26","author":[{"given":"J.-Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cannata-And\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Feron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Genant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Ringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,14]]},"reference":[{"key":"3109_CR1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","volume":"8","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Borgstrom F, Compston J et al (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144","journal-title":"Arch Osteoporos"},{"key":"3109_CR2","doi-asserted-by":"crossref","unstructured":"Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75\u00a0years. Bone 46:440\u2013446","DOI":"10.1016\/j.bone.2009.08.052"},{"key":"3109_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00198-009-0924-z","volume":"21","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157\u2013165","journal-title":"Osteoporos Int"},{"key":"3109_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Ben SW et al (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205\u2013224","journal-title":"Pharmacoeconomics"},{"key":"3109_CR5","unstructured":"European Medicines Agency (2014) Strontium ranelate. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000560\/WC500045525.pdf . Accessed 18 July 2014"},{"key":"3109_CR6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/14740338.2014.939169","volume":"13","author":"JY Reginster","year":"2014","unstructured":"Reginster JY (2014) Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf 13:1209\u20131213","journal-title":"Expert Opin Drug Saf"},{"key":"3109_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.maturitas.2014.03.011","volume":"78","author":"J Compston","year":"2014","unstructured":"Compston J (2014) Strontium ranelate lives to fight another day. Maturitas 78:75\u201376","journal-title":"Maturitas"},{"key":"3109_CR8","unstructured":"European Medicines Agency (2013) Assessment report\u2014periodic safety update report (EPAR - Protelos-H-C-560-PSU31). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000560\/WC500147168.pdf . Accessed 3 Feb 2014"},{"key":"3109_CR9","doi-asserted-by":"crossref","unstructured":"Audran M, Jakob FJ, Palacios S et al (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3\u00a0years. Rheumatol Int 33:2231\u20132239","DOI":"10.1007\/s00296-012-2594-y"},{"key":"3109_CR10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","volume":"25","author":"C Cooper","year":"2014","unstructured":"Cooper C, Fox KM, Borer JS (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case\u2013control study in the CPRD. Osteoporos Int 25:737\u2013745","journal-title":"Osteoporos Int"},{"key":"3109_CR11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","volume":"25","author":"B Abrahamsen","year":"2014","unstructured":"Abrahamsen B, Grove EL, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25:757\u2013762","journal-title":"Osteoporos Int"},{"key":"3109_CR12","doi-asserted-by":"crossref","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A (2014) Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 73:1037\u20131043","DOI":"10.1136\/annrheumdis-2014-205283"},{"key":"3109_CR13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"3109_CR14","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"3109_CR15","doi-asserted-by":"crossref","unstructured":"Kanis JA, Johansson H, Od\u00e9n A et al. (2014) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications. Abstract OC25. Presented at the World Congress on Osteoporosis and Osteoarthritis and Musculoskeletal Diseases. WCO-IOF-ESCEO, Seville, Spain","DOI":"10.1007\/s00198-014-2642-4"},{"key":"3109_CR16","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/S0140-6736(14)60688-7","volume":"383","author":"E Falaschetti","year":"2014","unstructured":"Falaschetti E, Mindell J, Knott C et al (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383:1912\u20131919","journal-title":"Lancet"},{"key":"3109_CR17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.maturitas.2011.10.005","volume":"71","author":"TJ Aspray","year":"2012","unstructured":"Aspray TJ, Francis RM (2012) Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas 71:76\u201378","journal-title":"Maturitas"},{"key":"3109_CR18","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2005.12.018","volume":"119","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119:S12\u2013S17","journal-title":"Am J Med"},{"key":"3109_CR19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811\u2013818","journal-title":"Osteoporos Int"},{"key":"3109_CR20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","volume":"25","author":"M Tadrous","year":"2014","unstructured":"Tadrous M, Wong L, Mamdani MM et al (2014) Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int 25:1225\u20131235","journal-title":"Osteoporos Int"},{"key":"3109_CR21","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1007\/s00198-011-1668-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Cooper C, Hiligsmann M et al (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565\u20132573","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3109-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3109-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T06:33:00Z","timestamp":1566541980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3109-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,14]]}}}